Nanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy

LAS VEGAS, Oct. 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has entered into a Contract Research Agreement with the Universidad de Sevilla ("USE") to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based chronic pain formulations.

GB Sciences has identified USE as having top-notch nanotechnology experts, excellent research facilities, and state-of-the art scientific equipment. The group working with GB Sciences on this important project is headed by Dr. Mercedes Fernández Arévalo and Dr. Lucia Martin Banderas.

"Our research group has been diligently working on the development of new oral drug delivery systems. We design nanometric systems able to offer the greatest control and effectiveness of the drug taking into account physicochemical and biopharmaceutical drug properties. This is the case of our recently developed cannabinoid nanosystems. More recently, we were involved in the development of nanosystems intended to actively target specific diseases, which involves developing more complex nanosystems with highly specific surface properties," said Dr. Mercedes Fernández Arévalo (I+DNanomed, Website: grupos.us.es/idnanomed/).

In May of 2017, GB Sciences filed a provisional patent application for myrcene-containing complex mixtures for chronic pain relief (among other uses). GB Sciences is now collaborating with USE to develop a suitable nanotech-based delivery mechanism that would provide a steady release of active ingredients over time, which is very desirable for chronic conditions.

"Some patients who need relief from chronic pain, do not want the psychoactive effects of THC found in other cannabis-based therapies. GB Sciences' THC-free pain formulation may be just what they need," said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "However, we believe that developing a time-released formulation in conjunction with USE would increase the effectiveness of our chronic pain therapy and improve patient compliance. Time-release formulas are taken less frequently and achieve more consistent pain relief over time."

"GB Sciences is proud of our affiliation with USE," said John Poss, CEO of GB Sciences, "together we will develop a line of time release formulations for medications to best meet the needs of patients all around the world."

About GB Sciences, Inc.

Growblox Life Sciences, LLC is a wholly owned subsidiary of GB Sciences, Inc. (GBLX) that is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

About Universidad de Sevilla

Universidad de Sevilla (USE) is an institution with more than five centuries of history, with an accredited academic tradition, and with recognition as an International Campus of Excellence. All of our qualifications are adapted to the European Higher Education Area and cover all areas of knowledge that provide a public higher education service through study, teaching and research, as well as the generation, development and dissemination of knowledge at the service of Society and Citizenship. USE has made an important effort to improve its research facilities and scientific equipment, which has made it possible to be a Center for Research Excellence that answers public calls for research, engages in collaborations with companies, and creates an important patent portfolio. Our Campus model is integrated in to the city of Sevilla, unfolding in several urban areas and contributing to the vibrancy of the city. www.us.es

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Liz Bianco Publicity Director, liz@gbsciences.com, http://gbsciences.com
Tom Arcuragi, COO, tom@gbsciences.com

View original content with multimedia:http://www.prnewswire.com/news-releases/nanotechnology-research-collaboration-with-universidad-de-sevilla-to-create-time-released-formulation-for-gb-sciences-thc-free-chronic-pain-therapy-300533913.html

SOURCE GB Sciences, Inc.